The North America Breast Biopsy Devices Market is experiencing significant growth due to the rising prevalence of breast cancer, increased adoption of advanced biopsy technologies, and supportive regulatory policies. The market was valued at USD 520 Million in 2025 and is expected to reach USD 1,050 Million by 2035, growing at a CAGR of 6.5% from 2024 to 2035. The U.S. continues to dominate market revenue owing to robust healthcare infrastructure and early adoption of innovative biopsy solutions.
The economic impact of tariffs on "North America Breast Biopsy Devices Market".
Market Growth Drivers
Increasing Incidence of Breast Cancer: The growing incidence of breast cancer in North America is a primary driver for the breast biopsy devices market. According to Hologic, Inc., breast cancer remains one of the most commonly diagnosed cancers among women, spurring demand for accurate and minimally invasive diagnostic techniques. As early detection significantly improves survival rates, healthcare providers are investing in advanced biopsy systems like Mammotome and core needle devices, ensuring faster and more precise diagnosis. This trend is also encouraged by awareness campaigns and screening programs, supported by government and non-profit organizations.
Technological Advancements in Biopsy Devices: Leading manufacturers such as BD (Becton, Dickinson and Company) are at the forefront of developing next-generation biopsy devices with enhanced imaging, automation, and sample collection precision. The integration of real-time imaging guidance, vacuum-assisted biopsy systems, and digital pathology solutions has markedly improved the diagnostic yield and minimized patient discomfort. These technological improvements are attracting investments from both public and private sectors, thus accelerating the adoption and replacement cycle of existing biopsy equipment across North American hospitals and diagnostic centers.
Market Trends
Growing Adoption of Minimally Invasive Procedures: There is an increasing preference for minimally invasive biopsy techniques such as vacuum-assisted and ultrasound-guided biopsies in the North American market. Companies like Devicor Medical Products (a division of Leica Biosystems) are witnessing growing demand for procedures that reduce recovery time and post-operative complications. This trend aligns with patient-centric care models and lowers the burden on healthcare facilities, supporting market expansion.
Integration of Artificial Intelligence (AI) and Digital Pathology: The adoption of AI-powered imaging and digital pathology in breast biopsy diagnostics is rising rapidly. Hologic, Inc. and GE Healthcare are investing in machine learning systems that assist clinicians in interpreting biopsy results more accurately and efficiently. These advancements help reduce diagnostic errors and streamline workflow, creating new growth avenues for market players.
Market Opportunities
Expansion in Ambulatory Surgical Centers: The growing number of ambulatory surgical centers (ASCs) in North America presents a significant opportunity for market players. By targeting these centers with compact and cost-efficient biopsy devices, companies such as BD can expand their customer base and improve accessibility to advanced diagnostics.
Emerging Personalized Medicine Approaches: The focus on personalized medicine and targeted therapies in oncology is propelling the demand for high-precision biopsy devices. Manufacturers with products enabling better molecular profiling are well-positioned to capitalize on this opportunity, as precision diagnostics are integral to individualized breast cancer treatment plans.
North America Breast Biopsy Devices Market Revenue (USD Million), 2020-2035
The chart illustrates the revenue growth of the North America Breast Biopsy Devices Market from 2020 to 2035. The market grew from USD 350 Million in 2020 to an estimated USD 520 Million in 2025, demonstrating steady adoption of innovative biopsy solutions. Post-2025, driven by technological advances and expansion of healthcare infrastructure, the market is projected to continue its upward trajectory and reach USD 1,050 Million by 2035, with a CAGR of 6.5%. Key revenue contributors include the U.S. and Canada, propelled by robust screening programs and a rising emphasis on early cancer detection.
North America Breast Biopsy Devices Market Share by Region (%) - 2025
The 2025 pie chart highlights the regional market share distribution. The United States holds the dominant share at 73%, attributed to advanced healthcare infrastructure and favorable reimbursement policies. Canada follows with 17% market share, reflecting increasing adoption of modern diagnostic technologies. Mexico accounts for 7%, driven by gradual healthcare investments. Other North American territories collectively represent 3%. The distribution showcases the U.S.'s leadership in market revenue, with Canada and Mexico acting as growth frontiers for the next decade.
Recent Developments in the North America Breast Biopsy Devices Market (Last 6 Months)
In April 2024, Hologic, Inc. announced the launch of the Brevera® Breast Biopsy System with CorLumina® Imaging Technology in North America. This all-in-one device merges tissue acquisition and imaging, enabling faster and more accurate biopsies at the point of care. The product aims to streamline workflow and reduce the need for repeat procedures, reinforcing Hologic's leadership in biopsy innovation.
In May 2024, BD (Becton, Dickinson and Company) revealed a strategic partnership with Mayo Clinic to co-develop AI-powered biopsy diagnostic tools. This collaboration leverages BD's biopsy device technology and Mayo Clinic's expertise in radiology and digital pathology, aiming to accelerate accurate cancer detection and facilitate quicker clinical decisions in breast health management.
In June 2024, Devicor Medical Products (Leica Biosystems) introduced an upgraded Mammotome Elite system featuring improved ergonomics and real-time wireless connectivity for data transfer. The new system enhances user experience and integrates seamlessly with digital pathology platforms, supporting efficient biopsy procedures and contemporaneous data analysis for clinicians across major North American hospitals.
Press Releases